Clinical Trial Update: Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. [Phase 2]

View source ↗

Summary

Phase II study evaluating HLX43 alone or in combination with immune checkpoint inhibitors for locally advanced, recurrent, or metastatic triple-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Phase 2 | Status: NOT_YET_RECRUITING